ArticleCureus2025
Temperament Traits as Key Modulators of Depression and Anxiety in Hyperthyroidism: Implications for Personalized Treatment.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The relationship between thyroid hormone dysfunction and psychiatric symptoms is complex, with hyperthyroidism frequently presenting alongside mood and anxiety disorders. Temperament traits, enduring psychological characteristics, may significantly influence the clinical manifestation of depression and anxiety in hyperthyroid patients, yet they remain understudied. This study aimed to determine whether specific temperament traits in hyperthyroid individuals correlate with anxiety and depressive symptoms and explore their implications for personalized clinical management. Methods A total of 59 patients diagnosed with hyperthyroidism and 40 healthy controls participated in this study. All participants underwent clinical assessment, thyroid function testing (thyroid-stimulating hormone (TSH), T3, T4), and completed the Hospital Anxiety and Depression Scale (HADS) and the Temperament Evaluation of Memphis, Pisa, Paris, and San Diego Autoquestionnaire (TEMPS-A). Demographic and clinical parameters, including age, gender, body mass index (BMI), blood pressure, smoking status, and family history, were also documented. Statistical analyses included Mann-Whitney U tests for group comparisons, Spearman's correlation analysis for relationships between temperament traits and psychiatric symptoms, and generalized linear models (GLM) to identify predictors of depressive symptoms. Results Hyperthyroid patients exhibited significantly higher anxiety scores compared to controls (p<0.001), whereas depressive symptoms, although elevated, did not reach statistical significance (p>0.05). Temperament assessment revealed significantly increased depressive, cyclothymic, irritable, and anxious traits in patients compared to controls (p<0.001). Hyperthymic temperament showed no significant difference between groups. A notable positive correlation emerged between irritable temperament and increased depressive symptoms (r=0.635, p<0.001). Depressive temperament significantly predicted higher depression scores, while hyperthymic temperament appeared protective, associated with reduced depressive symptoms (p<0.05). Conclusions These findings highlight the importance of temperament traits as critical modulators of psychiatric outcomes in hyperthyroidism. Irritable and depressive temperaments may increase vulnerability to depressive disorders, whereas hyperthymic temperament could offer resilience. Integrating temperament assessment into clinical practice may enhance diagnostic precision and inform personalized therapeutic approaches, improving patient outcomes and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.